Interferon-gamma in driving crypt hyperplasia in celiac disease

Interferon-gamma plays a crucial role in driving crypt hyperplasia, a hallmark of celiac disease and other inflammatory intestinal disorders. Crypt hyperplasia refers to the abnormal elongation and proliferation of epithelial crypts in the intestinal lining, which is commonly observed in active celiac disease.

Research using mass spectrometry-based tissue proteomics revealed strong interferon-gamma activity in the epithelial crypt zone of patients with active celiac disease. This was evidenced by increased expression of major histocompatibility complex (MHC) molecules and decreased levels of proteins involved in fatty acid metabolism, indicating significant molecular changes in the intestinal epithelium.

To further investigate, experiments in wild-type mice demonstrated that administration of interferon-gamma reproduced the morphological and molecular features of crypt hyperplasia, confirming its role in driving this pathological process. Importantly, mice lacking interferon-gamma receptors specifically in gut epithelial cells did not develop crypt hyperplasia when exposed to interferon-gamma, providing direct evidence that interferon-gamma acts on epithelial cells to induce these changes.

Overall, interferon-gamma is a direct driver of crypt hyperplasia in celiac disease, highlighting its critical role in the disease's pathogenesis. It may also play a similar role in other inflammatory intestinal disorders involving interferon-gamma signaling, making it a potential therapeutic target for these conditions.